ISU305 (eculizumab biosimilar) / ISU Abxis, Pharmsynthez - LARVOL DELTA

ISU Abxis Receives Russian Product Approval for Paroxysmal Nocturnal Hemoglobinuria Treatment (The Asia Business Daily) - "After successfully completing Phase 3 clinical trials in Russia, the product has now obtained approval."

Approval • Paroxysmal Nocturnal Hemoglobinuria

Isu Abzis completes registration for ISU305 Phase I clinical trial for Soliris biosimilar [Google Translation] (channelin.co.kr) - "IsuApjis announced...that it has completed the registration of Phase 1 clinical trial of ISU305, a biosimilar of Solisris, a treatment for paroxysmal nocturnal hemoglobinosis...After completing the final enrollment, Isuap is preparing a clinical trial result report (CSR) by next year, and then selects a partner and enters the third phase of the clinical trial."

Trial status